{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:32:09Z","timestamp":1784197929316,"version":"3.55.0"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Assessment of minimal residual disease (MRD) is becoming a standard diagnostic tool for curable hematological malignancies such as chronic and acute myeloid leukemia. Multiple myeloma (MM) remains an incurable disease, as a major portion of patients even in complete response eventually relapse, suggesting that residual disease remains. Over the past decade, the treatment landscape of MM has radically changed with the introduction of new effective drugs and the availability of immunotherapy, including targeted antibodies and adoptive cell therapy. Therefore, conventional serological and morphological techniques have become suboptimal for the evaluation of depth of response. Recently, the International Myeloma Working Group (IMWG) introduced the definition of MRD negativity as the absence of clonal Plasma cells (PC) with a minimum sensitivity of &amp;lt;10<jats:sup>\u22125<\/jats:sup> either by next-generation sequencing (NGS) using the LymphoSIGHT platform (Sequenta\/Adaptative) or by next-generation flow cytometry (NGF) using EuroFlow approaches as the reference methods. While the definition of the LymphoSIGHT platform (Sequenta\/Adaptive) as the standard method derives from its large use and validation in clinical studies on the prognostic value of NGS-based MRD, other commercially available options exist. Recently, the LymphoTrack assay has been evaluated in MM, demonstrating a sensitivity level of 10<jats:sup>\u22125<\/jats:sup>, hence qualifying as an alternative effective tool for MRD monitoring in MM. Here, we will review state-of-the-art methods for MRD assessment by NGS. We will summarize how MRD testing supports clinical trials as a useful tool in dynamic risk-adapted therapy. Finally, we will also discuss future promise and challenges of NGS-based MRD determination for clinical decision-making. In addition, we will present our real-life single-center experience with the commercially available NGS strategy LymphoTrack-MiSeq. Even with the limitation of a limited number of patients, our results confirm the LymphoTrack-MiSeq platform as a cost-effective, readily available, and standardized workflow with a sensitivity of 10<jats:sup>\u22125<\/jats:sup>. Our real-life data also confirm that achieving MRD negativity is an important prognostic factor in MM.<\/jats:p>","DOI":"10.3389\/fonc.2022.932852","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T05:24:33Z","timestamp":1660627473000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Valeria","family":"Ferla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Masottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Malato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Marktel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Lupo Stanghellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tresoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Marcatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-198788","article-title":"The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma","volume":"114","author":"Chee","year":"2009","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2300","article-title":"Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry","volume":"35","author":"Matsue","year":"2017","journal-title":"Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0866","article-title":"New developments in diagnosis, prognosis, and assessment of response in multiple myeloma","volume":"22","author":"Landgren","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.094409","article-title":"Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse","volume":"99","author":"Pour","year":"2014","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18 f-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2018.07.006","article-title":"Noninvasive molecular monitoring in multiple myeloma patients using cell-free tumor DNA: A pilot study","volume":"20","author":"Biancon","year":"2018","journal-title":"J Mol Diagn"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.161414","article-title":"Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA","volume":"102","author":"Oberle","year":"2017","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13358","article-title":"Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients","volume":"104","author":"Vrabel","year":"2020","journal-title":"Eur J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0115-z","article-title":"Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing","volume":"32","author":"Guo","year":"2018","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0469-x","article-title":"Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients","volume":"33","author":"Mithraprabhu","year":"2019","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.0086","article-title":"Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma","volume":"31","author":"Kapoor","year":"2013","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2009.124370","article-title":"Serum free light chain ratio, total kappa\/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma","volume":"55","author":"Giarin","year":"2009","journal-title":"Clin Chem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.197","article-title":"Immunoglobulin heavy\/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients","volume":"27","author":"Ludwig","year":"2013","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bmt.1705194","article-title":"Cure of multiple myeloma \u2013 more hype, less reality","volume":"37","author":"Hari","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the medical research council myeloma IX study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: A pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: The MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.005","article-title":"Concordance of post-consolidation minimal residualdiseaseratesby multiparametric flow cytometry and next-generation sequencingin CASSIOPEIA","volume":"19","author":"Herve","year":"2019","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/blood.V130.Suppl_1.435.435","article-title":"Minimal residual disease in multiple myeloma: Final analysis of theIFM2009 trial","volume":"130","author":"Herv\u00e9","year":"2017","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237155","article-title":"The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements","volume":"15","author":"Cedena","year":"2020","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00860","article-title":"Minimal residual disease in multiple myeloma: Current landscape and future applications with immunotherapeutic approaches","volume":"10","author":"Kostopoulos","year":"2020","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-97746-1_9","article-title":"Minimal residual disease in multiple myeloma: Impact on response assessment, prognosis and tumor heterogeneity","volume":"1100","author":"Berger","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12659","article-title":"Immunoglobulin gene analysis as a tool for investigating human immune responses","volume":"284","author":"Dunn-Walters","year":"2018","journal-title":"Immunol Rev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.3390\/ijms20112832","article-title":"Minimal residual disease monitoring with next-generation sequencing methodologies in hematological malignancies","volume":"20","author":"S\u00e1nchez","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-Lenalidomide-Dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936","volume":"17","author":"Van Dongen","year":"2003","journal-title":"Leukemia"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402937","article-title":"Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR","volume":"17","author":"Gonz\u00e1lez","year":"2003","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211600","article-title":"Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma","volume":"14","author":"Rustad","year":"2019","journal-title":"PLoS One"},{"key":"B47","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood.V130.Suppl_1.739.739","article-title":"Daratumumab, lenalidomide, anddexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed orrefractory multiple myeloma (RRMM): updated efficacy and safety analysis ofpollux","volume":"130","author":"DM","year":"2017","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx340","article-title":"Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation","volume":"28","author":"Takamatsu","year":"2017","journal-title":"Ann Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00449","article-title":"Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma","volume":"9","author":"Yao","year":"2019","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in b-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750","article-title":"Evaluation of minimal residual disease (MRD)By next generation sequencing (NGS) is highly predictive of progression FreeSurvival in the IFM\/DFCI 2009 trial","volume":"376","author":"Herve","year":"2015"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Minimalresidual disease evaluation by multiparameter flowcytometry and next generationsequencing in the forte trial for newly diagnosed multiple myeloma patients","volume":"394","author":"Oliva","year":"2019","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147897","article-title":"Daratumumab (DARA) with bortezomib, thalidomide, and dexamethasone (VTd)in transplant-eligible patients (Pts) with newly diagnosed multiple Myeloma(NDMM): Analysis of minimal residual disease (MRD) negativity in CassiopeiaPart 1 and part 2","volume":"138","author":"Avet-Loiseau","year":"2021"},{"key":"B59","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","article-title":"Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial","volume":"11","author":"Oliva","year":"2021","journal-title":"Blood Cancer J"},{"key":"B60","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41408-017-0028-5","article-title":"MRD in multiple myeloma: more questions than answers","volume":"7","author":"Moreau","year":"2017","journal-title":"Blood Cancer J"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1386304","article-title":"Minimal residual disease analysis in myeloma - when, why and where","volume":"59","author":"Yanamandra","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00001","article-title":"Clinical applications and future directions of minimal residual disease testing in multiple myeloma","volume":"10","author":"Oliva","year":"2020","journal-title":"Front Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2895","article-title":"The role of minimal residual disease testing in myeloma treatment selection and drug development: Current value and future applications","volume":"23","author":"Anderson","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1059","article-title":"Minimal residual disease in myeloma: Application for clinical care and new drug registration","volume":"27","author":"Anderson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.4415\/ANN_21_04_05","article-title":"Measurable residual disease in multiple myeloma and in acute myeloid leukemia, an evolving topic","volume":"57","author":"Castelli","year":"2021","journal-title":"Ann Ist Super Sanita"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.801851","article-title":"Minimal residual disease assessment in multiple myeloma patients: Minimal disease with maximal implications","volume":"11","author":"Charalampous","year":"2021","journal-title":"Front Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40364-021-00328-2","article-title":"Minimal residual disease in multiple myeloma: current status","volume":"9","author":"Ding","year":"2021","journal-title":"biomark Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41408-020-0297-2","article-title":"Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma","volume":"10","author":"Gavriatopoulou","year":"2020","journal-title":"Blood Cancer J"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S1470-2045(18)30764-2","article-title":"Lenalidomide as maintenance for every newly diagnosed patient with multiple myeloma","volume":"20","author":"Mateos","year":"2019","journal-title":"Lancet Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.annonc.2021.10.001","article-title":"Corrigendum to 'Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up': [Ann oncol 2021; 32(3): 309-322]","volume":"33","author":"Dimopoulos","year":"2022","journal-title":"Ann Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.26512","article-title":"Current approaches to management of newly diagnosed multiple myeloma","author":"Goel","year":"2022","journal-title":"Am J Hematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02083-8","article-title":"Treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma: A systematic literature review and network meta-analysis","author":"Facon","year":"2022","journal-title":"Adv Ther"},{"key":"B75","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.exphem.2021.03.005","article-title":"Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements-how low can you go","volume":"98","author":"Hansen","year":"2021","journal-title":"Exp Hematol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101149","article-title":"Monitoring minimal residual disease in the bone marrow using next generation sequencing","volume":"33","author":"Rustad","year":"2020","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.932852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T05:24:35Z","timestamp":1660627475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.932852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":76,"alternative-id":["10.3389\/fonc.2022.932852"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.932852","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"article-number":"932852"}}